Compare DexCom, Inc. (DXCM) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs STMicroelectronics NV — how do they compare? DexCom, Inc. trades at $78.55 (market cap $28.06B), while STMicroelectronics NV trades at $64.01 (market cap $59.83B). The key difference: STMicroelectronics NV is far larger — about 2.1× DexCom, Inc.'s market cap, and STMicroelectronics NV pays a 0.53% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | STM | |
|---|---|---|
Market Cap | $28.06B | $59.83B |
Sector | Health | Financials |
52-Week High | $89.53 | $79.91 |
52-Week Low | $54.84 | $21.20 |
Enterprise Value | $27.03B | $58.04B |
Dividend Yield | — | 0.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
STM trades at $70.13, up 2.42% today, with a neutral technical signal and bullish moving averages. The stock shows mixed earnings performance with recent misses but maintains analyst optimism with a $72.33 consensus target. Revenue declined from $17.3B in 2023 to $11.8B in 2025, with net margins compressing to 1.19%, though cash flow improved to $555M. Recent news highlights AI partnerships with AWS and NVIDIA as potential growth catalysts.
Outlook remains cautiously optimistic given AI expansion opportunities, but elevated P/E of 423.44 and margin pressures present risks. The stock offers modest upside to consensus target with support from institutional buy ratings, though investors should monitor Q2 2026 earnings due soon against expectations of $0.26 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
